Shattuck Labs, Inc. (NASDAQ:STTK) Receives $7.50 Consensus Price Target from Analysts

Shattuck Labs, Inc. (NASDAQ:STTK) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $7.50.

A number of equities analysts have recently commented on STTK shares. Leerink Partnrs upgraded shares of Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Leerink Partners began coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They set an “outperform” rating and a $4.00 target price for the company.

Shattuck Labs Price Performance

Shares of NASDAQ:STTK opened at $1.20 on Monday. The company’s 50 day simple moving average is $1.24 and its 200 day simple moving average is $1.55. The stock has a market capitalization of $57.29 million, a price-to-earnings ratio of -0.78 and a beta of 1.66. Shattuck Labs has a 1 year low of $0.94 and a 1 year high of $11.76.

Institutional Investors Weigh In On Shattuck Labs

A number of institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Shattuck Labs by 0.9% in the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock valued at $3,184,000 after acquiring an additional 8,133 shares during the last quarter. Atom Investors LP purchased a new position in Shattuck Labs in the third quarter valued at about $35,000. JPMorgan Chase & Co. boosted its stake in Shattuck Labs by 63.2% in the third quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock valued at $96,000 after acquiring an additional 10,667 shares during the last quarter. Readystate Asset Management LP purchased a new position in Shattuck Labs in the third quarter valued at about $39,000. Finally, MetLife Investment Management LLC boosted its stake in Shattuck Labs by 129.1% in the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock valued at $86,000 after acquiring an additional 13,859 shares during the last quarter. 58.74% of the stock is owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.